Type and scope of trials include:
- Early to mid-phase trials exploring safety or biomarkers to justify larger studies;
- Trial population, including genetic or sporadic forms of ALS, healthy subjects, and/or asymptomatic carriers of ALS-linked genetic mutations;
- Therapeutic approaches: Novel or modified approaches for ALS (either disease-modifying or symptomatic), including small molecules, genetic therapies, stem cell approaches, peptides, antibodies, and antisense therapies.
Trials awarded will receive up to $1,000,000 over 2 to 3 years, with payments being milestone-based. Requests for Applications will be launched annually, around December, with awardees announced approximately 6 months after the initial launch. The process will entail the following:
- Researchers interested in receiving a grant will submit a short letter of intent, around 1-2 pages, listing scope of the proposed trial, novelty of the idea and how it aligns with the Association’s priorities.
- Association staff will review letters of intent, selecting projects that align with the original request for application.
- Selected researchers will be invited to submit a full proposal, approximately 8-12 pages, that details the scientific plan, research team, budget and feasibility. Proposals will be peer reviewed by independent external experts.
- Selected proposals will be submitted to the Research Committee for review, discussion and final approval, including funding amount.
Once approved for funding, the project will go into the grant management stage. The designated Association staff will:
- Notify the selected researcher.
- Develop, negotiate and issue the contract that outlines milestones, expectations and approved uses for the grant.
- Monitor progress and issue grant payments once milestones are reached.
Grantees will be expected to adhere to the ALS Association’s grant award terms and conditions. This includes:
- Establish and maintain effective internal controls to ensure the grant award will be used in compliance with the stated requirements.
- Agree to perform the project as proposed.
- Prudently manage the award provided and operate the trial in accordance with the provisions of the grant.
- Seek approval by the Association for any adjustment to the project where Association dollars are used prior to the change.
Key Dates
- Full Proposal Due (by invitation only): April 12, 2024, 5 p.m. US ET
- Anticipated Award Decision: June 2024
- Anticipated Earliest Start Date: July 2024
Sign Up for More Information
Fill out the form below to receive more information about The Hoffman ALS Clinical Trial Awards Program straight to your inbox.
